Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Rheumatic immune-related adverse events from cancer immunotherapy
Leonard H. Calabrese, Cassandra Calabrese, Laura C. Cappelli
Nature Reviews Rheumatology (2018) Vol. 14, Iss. 10, pp. 569-579
Closed Access | Times Cited: 193

Showing 1-25 of 193 citing articles:

Tertiary lymphoid structures in cancer
Ton N. Schumacher, Daniela S. Thommen
Science (2022) Vol. 375, Iss. 6576
Closed Access | Times Cited: 635
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
John B.A.G. Haanen, Michel Obéid, Lavinia Spain, et al.
Annals of Oncology (2022) Vol. 33, Iss. 12, pp. 1217-1238
Open Access | Times Cited: 591
Recent Advances in Hyperthermia Therapy‐Based Synergistic Immunotherapy
Mengyu Chang, Zhiyao Hou, Man Wang, et al.
Advanced Materials (2020) Vol. 33, Iss. 4
Closed Access | Times Cited: 347
Moving towards personalized treatments of immune-related adverse events
Khashayar Esfahani, Arielle Elkrief, Cassandra Calabrese, et al.
Nature Reviews Clinical Oncology (2020) Vol. 17, Iss. 8, pp. 504-515
Closed Access | Times Cited: 247
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors
Marie Kostine, Axel Finckh, Clifton O. Bingham, et al.
Annals of the Rheumatic Diseases (2020) Vol. 80, Iss. 1, pp. 36-48
Open Access | Times Cited: 217
Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action
Zena Willsmore, Ben G T Coumbe, Silvia Crescioli, et al.
European Journal of Immunology (2021) Vol. 51, Iss. 3, pp. 544-556
Open Access | Times Cited: 139
Biomedical polymers: synthesis, properties, and applications
Wei‐Hai Chen, Qi‐Wen Chen, Qian Chen, et al.
Science China Chemistry (2022) Vol. 65, Iss. 6, pp. 1010-1075
Open Access | Times Cited: 127
A digital single-molecule nanopillar SERS platform for predicting and monitoring immune toxicities in immunotherapy
Junrong Li, Alain Wuethrich, Abu Ali Ibn Sina, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 104
Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases
Alice Tison, Soizic Garaud, Laurent Chiche, et al.
Nature Reviews Rheumatology (2022) Vol. 18, Iss. 11, pp. 641-656
Closed Access | Times Cited: 100
Cytokine Release Syndrome in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Case Series of 25 Patients and Review of the Literature
Sen Hee Tay, Michelle Min Xuan Toh, Yee Liang Thian, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 70
Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
Sang T. Kim, Yanshuo Chu, Mercy Misoi, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 70
A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis
Jay Tuttle, Edit Drescher, Jesus Abraham Simón Campos, et al.
New England Journal of Medicine (2023) Vol. 388, Iss. 20, pp. 1853-1862
Closed Access | Times Cited: 64
Lactate modulates RNA splicing to promote CTLA-4 expression in tumor-infiltrating regulatory T cells
Rui Ding, Xiaoyan Yu, Zhilin Hu, et al.
Immunity (2024) Vol. 57, Iss. 3, pp. 528-540.e6
Closed Access | Times Cited: 27
Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy
Yan Zhang, Xuexiang Du, Mingyue Liu, et al.
Cell Research (2019) Vol. 29, Iss. 8, pp. 609-627
Open Access | Times Cited: 109
Increased incidence of venous thromboembolism with cancer immunotherapy
Joanna Roopkumar, Shadi Swaidani, Ann S. Kim, et al.
Med (2021) Vol. 2, Iss. 4, pp. 423-434.e3
Open Access | Times Cited: 96
Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer
Karan Mediratta, Sara El‐Sahli, Vanessa M. D’Costa, et al.
Cancers (2020) Vol. 12, Iss. 12, pp. 3529-3529
Open Access | Times Cited: 86
Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade
Zia Khan, Christian Hammer, Jonathan Carroll, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 67
Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events
Remo Poto, Teresa Troiani, Gjada Criscuolo, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 66
Combination of epigenetic regulation with gene therapy-mediated immune checkpoint blockade induces anti-tumour effects and immune response in vivo
Huapan Fang, Zhaopei Guo, Jie Chen, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 63
Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer
Md. Mominur Rahman, Tapan Behl, Md. Rezaul Islam, et al.
Molecules (2022) Vol. 27, Iss. 12, pp. 3798-3798
Open Access | Times Cited: 43
Early-Stage Triple-Negative Breast Cancer Journey: Beginning, End, and Everything in Between
Hyo S. Han, Praveen Vikas, Ricardo Costa, et al.
American Society of Clinical Oncology Educational Book (2023), Iss. 43
Closed Access | Times Cited: 36
Tertiary lymphoid structures are critical for cancer prognosis and therapeutic response
Qianqian Zhang, Suhui Wu
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 35
Epidemiology of the idiopathic inflammatory myopathies
Thomas Khoo, James B Lilleker, Bernard Yu‐Hor Thong, et al.
Nature Reviews Rheumatology (2023) Vol. 19, Iss. 11, pp. 695-712
Closed Access | Times Cited: 33
Nanodrug removes physical barrier to promote T-cell infiltration for enhanced cancer immunotherapy
Zecong Xiao, Yitong Tan, Yujun Cai, et al.
Journal of Controlled Release (2023) Vol. 356, pp. 360-372
Closed Access | Times Cited: 26
Checkpoint inhibitor immune-related adverse events: A focused review on autoantibodies and B cells as biomarkers, advancements and future possibilities
John E. Taylor, Aesha Gandhi, Elin S. Gray, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 24
Page 1 - Next Page

Scroll to top